1.37

13.22% +0.16

After Hours: 1.39 0.02 +1.46%

Nextcure Inc (NXTC)

Overview News Price History Option Chain Why NXTC Down? Discussions Forecast

Nextcure Inc stock is currently priced at $1.37, with a 24-hour trading volume of 214.37K. It has seen a +13.22% increased in the last 24 hours and a -40.69% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $1.21 pivot point. If it approaches the $1.42 resistance level, significant changes may occur.

Previous Close:

$1.21

Open:

$1.2

24h Volume:

214.37K

Market Cap:

$38.23M

Revenue:

Net Income/Loss:

$-65.56M

P/E Ratio:

-0.5437

EPS:

-2.52

Net Cash Flow:

$-52.93M

1W Performance:

-4.86%

1M Performance:

-40.69%

6M Performance:

+28.04%

1Y Performance:

-12.18%

1D Range:

$1.20

$1.43

52W Range:

$0.98

$2.57

Nextcure Inc Stock (NXTC) Company Profile

Name

Nextcure Inc

Sector

Healthcare (1189)

Industry

Biotechnology (685)

Phone

240 399 4900

Address

9000 Virginia Manor Road, Suite 200, Beltsville, MD

Employee

Twitter

@nextcureinc

Next Earnings Date

2024-05-02

Latest SEC Filings

NXTC's Discussions on Twitter

Nextcure Inc Stock (NXTC) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-04-22	Downgrade	Ladenburg Thalmann	Buy → Neutral
Mar-01-22	Initiated	Ladenburg Thalmann	Buy
Mar-05-21	Upgrade	Truist	Hold → Buy
Jan-15-21	Downgrade	BofA Securities	Neutral → Underperform
Jul-16-20	Upgrade	The Benchmark Company	Hold → Buy
Jul-13-20	Downgrade	ROTH Capital	Buy → Neutral
Jul-13-20	Downgrade	SunTrust	Buy → Hold
Jun-01-20	Downgrade	BofA/Merrill	Buy → Neutral
Jun-01-20	Downgrade	The Benchmark Company	Buy → Hold
May-26-20	Initiated	JMP Securities	Mkt Outperform
Mar-24-20	Initiated	The Benchmark Company	Buy
Mar-02-20	Initiated	ROTH Capital	Buy
Jan-13-20	Initiated	SunTrust	Buy
Dec-05-19	Initiated	Needham	Buy
Nov-26-19	Initiated	BTIG Research	Buy
Jul-09-19	Initiated	BofA/Merrill	Buy
Jun-03-19	Initiated	Morgan Stanley	Overweight
Jun-03-19	Initiated	Piper Jaffray	Overweight

View All

Nextcure Inc Stock (NXTC) Latest News

NextCure to Present Phase 1b Data of NC410 in Combination with Pembrolizumab at ASCO 2024

GlobeNewswire Inc.

NextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024

GlobeNewswire Inc.

Nextcure Inc Stock (NXTC) Financials Data

Nextcure Inc (NXTC) Net Income 2024

NXTC net income (TTM) was -$65.56 million for the quarter ending September 30, 2023, a +11.85% increase year-over-year.

Nextcure Inc (NXTC) Cash Flow 2024

NXTC recorded a free cash flow (TTM) of -$52.92 million for the quarter ending September 30, 2023, a +12.52% increase year-over-year.

Nextcure Inc (NXTC) Earnings per Share 2024

NXTC earnings per share (TTM) was -$2.35 for the quarter ending September 30, 2023, a +12.31% growth year-over-year.

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is in Phase I for novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1; NC762, an immunomedicine targeting a molecule called human B7 homolog 4 protein, or B7-H4; and NC525, a novel LAIR-1 antibody which is in Preclinical trails that targets acute myeloid leukemia, blast cells, and leukemic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. The company has a license agreement with Yale University. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.